News

24 February 2026

We have successfully installed our second iPHASE MultiSyn module, completing our integrated production platform for cyclotron produced Gallium 68 radiopharmaceuticals and establishing a streamlined, high capacity manufacturing workflow. Within this configuration, the first MultiSyn module is dedicated to the purification of cyclotron produced Gallium 68, ensuring a high purity radionuclide input. The purified Gallium 68 […]Read more

05 December 2025

CIRC has entered a strategic partnership with Cyclotek to advance radiopharmaceutical capabilities in Singapore and across the ASEAN region. This collaboration aims to accelerate the development, production, and clinical translation of next-generation radiopharmaceuticals, supporting both diagnostic imaging and targeted therapeutics. By combining CIRC’s strengths in research, clinical imaging, and translational science with Cyclotek’s extensive industry […]Read more

24 November 2025

CIRC was pleased to host a seminar featuring keynote speaker Dr Svetlana Selivanova, an internationally recognised expert in radiopharmaceutical chemistry and radiobiology. With more than 20 years of experience spanning early-stage radiopharmaceutical development to first-in-human clinical studies, Dr Selivanova has held senior research positions in both Canada and Switzerland. She currently serves as an Executive […]Read more

03 October 2025

Dr Bhanu Prakash KN represented CIRC at the 24th International Cancer Imaging Society (ICIS) Meeting and Annual Teaching Course, where he showcased several ongoing research projects in cancer imaging and AI. He presented two posters, including “Evaluating nnUNet for Liver Segmentation in Multiphasic MRI of Hepatocellular Carcinoma”, which was awarded First Prize in the poster […]Read more

05 August 2025

We are excited to jointly launch a practice changing next generation total body PET/CT (Hybrid Positron Emission Tomography and Computer Tomography) system with the National University Hospital (NUH), in collaboration with Siemens Healthineers. The system, which will be ready in November 2025, sets a new benchmark for molecular imaging and development of novel theranostics in […]Read more

23 May 2025

Two of our radiochemists represented the CIRC at the International Symposium on Radiopharmaceutical Sciences (iSRS) 2025. They actively contributed to the scientific programme, engaged with leaders in the field, and strengthened CIRC’s international network. During the exhibition, they also presented two posters showcasing ongoing work within our radiochemistry team: “A Gallium-68 Radiolabelled NOTA-Conjugated Evans Blue […]Read more

28 February 2025

CIRC collaboratively developed and GMP validated a novel Ac 225 based radiopharmaceutical, representing a significant scientific and translational milestone. In parallel, CIRC supported the sponsor with regulatory activities, including contributions to the FDA filing process. The radiopharmaceutical demonstrated high radiochemical purity, stability, and reproducibility, thereby establishing a robust and reliable manufacturing process for alpha emitter […]Read more

22 May 2024

Three of our radiochemists attended the Malaysian Society of Nuclear Medicine and Molecular Imaging Annual Scientific Meeting 2024 (MYNM 2024), where they actively contributed to scientific exchange in radiopharmaceutical development, GMP manufacturing, and regulatory science. One CIRC radiochemist delivered an oral presentation entitled “Generic Gallium 68 Labelling Strategy Utilizing iQS Synthesis Module in Compliance with […]Read more

31 May 2023

One of our senior radiochemists was invited as a speaker at the Molecular Imaging and Theranostics Symposium 2023 in Singapore. During the symposium, the presentation highlighted CIRC’s expertise in theranostics, with a focus on radiopharmaceutical development, GMP compliant manufacturing, and the translation of molecular imaging agents into clinical applications. The talk provided insights into CIRC’s […]Read more